Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07416695RecruitingPhase 1
Study of HLX3901 for advanced lung or neuroendocrine cancer
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
BeijingAges 18–75 - NCT06819774RecruitingPhase 3
Testing cetirizine injection for acute hives
This trial tests an injectable medication (cetirizine, a type of antihistamine) to see if it quickly relieves itching and hives in adults with acute (short-term) hives. It is for people whose hives have lasted less than 6 weeks and who still have bothersome symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07415863RecruitingPhase 1/Phase 2
Study of SYS6043 for advanced solid tumors
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT07412327Recruiting
Proton therapy for early stage lung cancer
This trial tests a precise form of proton radiation for people with early stage lung cancer who cannot have surgery. It aims to see if this treatment is effective and safe.
Guangzhou, GuangdongAges 18 years+ - NCT07405970RecruitingPhase 3
Testing MIL62 for active lupus
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
BeijingAges 18–80 - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07371208RecruitingPhase 2
Sac-TMT plus immunotherapy before surgery for triple-negative breast cancer
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07364513RecruitingPhase 1
Safety study of IMSB301 for type 1 interferon disorders
This study tests an experimental drug (IMSB301) for people with rare genetic conditions that cause too much type 1 interferon activity (a part of the immune system). The goal is to see if the drug is safe and can help reduce symptoms.
SydneyAges 12 years+ - NCT07354269RecruitingPhase 4
Polio vaccine study for adolescents and adults
This trial tests a polio vaccine (sIPV) in healthy people aged 7-50 years. It aims to see how safe and effective the vaccine is, and may help protect against polio.
Dingxi, GansuAges 3 months–50 years - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06852287RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct and gallbladder cancer
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
Tianjin, TiaAges 18 years+ - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT06863506RecruitingPhase 2
Study of Befotertinib for non-small cell lung cancer with uncommon EGFR mutations
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Hangzhou, ZhejiangAges 18 years+ - NCT07331155RecruitingPhase 2
LBL-024 combo for advanced esophageal cancer
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07318103RecruitingPhase 2
Study of HRS-9057 for fluid retention in heart failure
This trial tests an investigational drug, HRS-9057, in people hospitalized with heart failure who still have fluid buildup despite taking standard diuretics. The goal is to see if HRS-9057 helps remove excess fluid better than current treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT07309276RecruitingPhase 2
Study of JS212 for advanced lung cancer
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07299123Enrolling by invitationPhase 1/Phase 2
Stem cell transplant with cord cells for severe aplastic anemia
This trial tests a new way to treat severe aplastic anemia by combining a stem cell transplant from a half-matched donor with special stem cells from umbilical cord blood. The goal is to help your body make healthy blood cells again.
BeijingAges 6–60 - NCT06879782RecruitingPhase 3
Eye drops for dry eye disease: a phase 3 study
This study tests an eye drop called lifitegrast for people with dry eye disease. It looks at whether the drops can improve eye comfort, reduce dryness, and help eye surface health. You may be able to join if you have had dry eye symptoms and used artificial tears in the past month.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07289477RecruitingPhase 1
Study of NouvNeu001 for Multiple System Atrophy
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Beijing, Beijing MunicipalityAges 30–70
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.